131 related articles for article (PubMed ID: 14525545)
1. Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.
Clements M; Law M; Pedersen C; Kaldor J;
HIV Med; 2003 Oct; 4(4):332-7. PubMed ID: 14525545
[TBL] [Abstract][Full Text] [Related]
2. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
Lancet; 2000 Apr; 355(9210):1131-7. PubMed ID: 10791375
[TBL] [Abstract][Full Text] [Related]
3. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
[TBL] [Abstract][Full Text] [Related]
5. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.
Lodi S; Phillips A; Touloumi G; Geskus R; Meyer L; Thiébaut R; Pantazis N; Amo JD; Johnson AM; Babiker A; Porter K;
Clin Infect Dis; 2011 Oct; 53(8):817-25. PubMed ID: 21921225
[TBL] [Abstract][Full Text] [Related]
6. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
; Lodwick RK; Sabin CA; Porter K; Ledergerber B; van Sighem A; Cozzi-Lepri A; Khaykin P; Mocroft A; Jacobson L; De Wit S; Obel N; Castagna A; Wasmuth JC; Gill J; Klein MB; Gange S; Riera M; Mussini C; Gutiérrez F; Touloumi G; Carrieri P; Guest JL; Brockmeyer NH; Phillips AN
Lancet; 2010 Jul; 376(9738):340-5. PubMed ID: 20638118
[TBL] [Abstract][Full Text] [Related]
7. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.
Bhaskaran K; Mussini C; Antinori A; Walker AS; Dorrucci M; Sabin C; Phillips A; Porter K;
Ann Neurol; 2008 Feb; 63(2):213-21. PubMed ID: 17894380
[TBL] [Abstract][Full Text] [Related]
8. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.
CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration
HIV Med; 2000 Oct; 1(4):224-31. PubMed ID: 11737353
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.
Wolbers M; Babiker A; Sabin C; Young J; Dorrucci M; Chêne G; Mussini C; Porter K; Bucher HC;
PLoS Med; 2010 Feb; 7(2):e1000239. PubMed ID: 20186270
[TBL] [Abstract][Full Text] [Related]
10. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
11. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
12. Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002.
Dorrucci M; Rezza G; Porter K; Phillips A;
J Infect Dis; 2007 Feb; 195(4):525-34. PubMed ID: 17230412
[TBL] [Abstract][Full Text] [Related]
13. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
Writing Committee for the CASCADE Collaboration
Arch Intern Med; 2011 Sep; 171(17):1560-9. PubMed ID: 21949165
[TBL] [Abstract][Full Text] [Related]
14. Risk of tuberculosis following HIV seroconversion in high-income countries.
Lodi S; del Amo J; d'Arminio Monforte A; Abgrall S; Sabin C; Morrison C; Furrer H; Muga R; Porter K; Girardi E;
Thorax; 2013 Mar; 68(3):207-13. PubMed ID: 23117980
[TBL] [Abstract][Full Text] [Related]
15. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.
Phillips A; Pezzotti P;
AIDS; 2004 Jan; 18(1):51-8. PubMed ID: 15090829
[TBL] [Abstract][Full Text] [Related]
16. Determinants of response to first HAART regimen in antiretroviral-naïve patients with an estimated time since HIV seroconversion.
Thiébaut R; Jacqmin-Gadda H; Walker S; Sabin C; Prins M; Del Amo J; Porter K; Dabis F; Chêne G;
HIV Med; 2006 Jan; 7(1):1-9. PubMed ID: 16313286
[TBL] [Abstract][Full Text] [Related]
17. Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?
Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration)
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):158-65. PubMed ID: 11588510
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.
May MT; Hogg RS; Justice AC; Shepherd BE; Costagliola D; Ledergerber B; Thiébaut R; Gill MJ; Kirk O; van Sighem A; Saag MS; Navarro G; Sobrino-Vegas P; Lampe F; Ingle S; Guest JL; Crane HM; D'Arminio Monforte A; Vehreschild JJ; Sterne JA;
Int J Epidemiol; 2012 Dec; 41(6):1807-20. PubMed ID: 23148105
[TBL] [Abstract][Full Text] [Related]
19. How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee.
AIDS; 1999 Jul; 13(10):1241-7. PubMed ID: 10416529
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
